Dr Lal PathLabs LALPATHLAB
North India's largest pathology lab chain, with a national network of labs, patient service centres and home collection
Mapped in 1 theme: Hospitals & Healthcare.
Where Dr Lal PathLabs sits in the supply chain
Dr Lal PathLabs appears in 1 supply-chain layer in one theme, Hospitals & Healthcare.
Hospitals & Healthcare › Pathology labs
OperatorOther companies in this layer
Revenue and profit
| ₹ Cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 2,087 | 2,017 | 2,227 | 2,461 | 2,763 |
| Net profit | 350 | 241 | 362 | 492 | 510 |
Latest-year revenue ₹2,763 Cr (FY26, company-wide).
Strengths
- Strong north India brand and B2C mix; net cash
- Patient volumes grew ~8% and samples ~11% in Q1 FY27 (ICICI Securities)
- Suburban Diagnostics extends it into Mumbai and the west
Risks
- Price competition from aggregators and hospital-led labs
- Growth outside its north India base is slower and costlier
Common questions
What does Dr Lal PathLabs do?
North India's largest pathology lab chain, with a national network of labs, patient service centres and home collection.
Where does Dr Lal PathLabs sit in the supply chain?
Dr Lal PathLabs (NSE: LALPATHLAB) is mapped in 1 supply-chain layer: Pathology labs (Hospitals & Healthcare).
Who are Dr Lal PathLabs' peers?
In the Pathology labs layer of Hospitals & Healthcare: Metropolis Healthcare, Thyrocare Technologies, Vijaya Diagnostic Centre, Fortis Healthcare and Neuberg Diagnostics (not NSE-listed).
What is Dr Lal PathLabs' market cap and valuation?
As of 6 Nov 2026: market cap ₹33,039 Cr, P/E 54.6x, ROCE 28.0%, ROE 22.3%, dividend yield 0.71%.